Health TrialsbyHealthPanel

Low-intensity Physical-cognitive Exercise and Cognitive Function

ConditionMild Cognitive Impairment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorChiang Mai University

About this trial

This study aims to examine the effects of low-intensity, combined physical-cognitive exercise on cognitive function of older people with mild cognitive impairment (MCI) and identify the mechanisms by which this exercise protocol exerts cognitive function. Older adults with MCI will be recruited to either an exercise or a control group. Low-intensity, combined physical-cognitive exercise will be prescribed to the exercise group 3 times per week for 3 months while the control group will maintain their routine lifestyle. It is hypothesized that at the end of the trial, participants in the exercise group will demonstrate significant improvement in cognitive performance and circulating biomarkers compared to baseline and the control group.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

meeting the criteria for MCI (or mNCD) based on the recent DSM-V criteria

comprehend instructions and able to comply with the study procedures

not taking any medications for their cognition and not planning to start medications during the study trial

Disqualifiers

presence of medical condition(s) unsafe to exercise or affect cognition and mobility

presence of depressive symptoms

exercise regularly

Trial design

Design model

Parallel

Treatments tested in this trial

  • combined physical-cognitive exercise

    Behavioral

    A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.

Treatment groups

64 Participants
are divided into 2 treatment groups
Group A: Low-intensity, combined physical-cognitive exerciseExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

ADAS-Cog

Alzheimer's Disease Assessment-cognitive subscale (ADAS-Cog) will be assessed at baseline and 12 weeks. The total scores range from 0-70 with higher scores indicating greater cognitive impairment.

Time frame
12 weeks
2

Memory

Logical memory test will be evaluated at baseline and 12 weeks.

Time frame
12 weeks
3

Executive function

Trail making test (TMT) part B-A will be evaluated at baseline and 12 weeks.

Time frame
12 weeks
4

Plasma BDNF

Level of plasma brain-derived neurotrophic factor will be assessed at baseline and 12 weeks.

Time frame
12 weekss

Secondary outcomes

1

Attention

Digit span forward-backward will be evaluated at baseline and 12 weeks

Time frame
12 weeks
2

Plasma IL-6

Level of plasma IL-6 will be assessed at baseline and 12 weeks.

Time frame
12 weeks
3

FGF21

Level of plasma fibroblast growth factor 21 (FGF21) will be assessed at baseline and 12 weeks.

Time frame
12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chiang Mai University

Lead sponsor

Source ClinicalTrials.gov
Apply now